Category: Press Release - Page 38 - Psychedelic Alpha

Read more about the article Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Post published:November 29, 2022
Post category:Press Release

Read more about the article atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Post published:November 29, 2022
Post category:Press Release

Read more about the article COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

Post published:November 28, 2022
Post category:Press Release

Read more about the article Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Post published:November 23, 2022
Post category:Press Release

Read more about the article MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY GROUP

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY GROUP

Post published:November 18, 2022
Post category:Press Release

Read more about the article MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Post published:November 17, 2022
Post category:News Press Release

Read more about the article atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Post published:November 17, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

Post published:November 17, 2022
Post category:Press Release

Read more about the article Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Post published:November 17, 2022
Post category:Press Release

Read more about the article MindMed to Participate in the Jefferies London Healthcare Conference

MindMed to Participate in the Jefferies London Healthcare Conference

Post published:November 11, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.